GM2-Activator Protein: A New Biomarker for Lung Cancer

Introduction: Effective biomarkers for early diagnosis of lung cancer are needed. A recent study demonstrated that urinary GM2-activator protein (GM2AP) level was increased in lung cancer patients. This study aims to validate the potential application of GM2AP as a biomarker for diagnosis of lung cancer. Methods: Serum and urine samples were obtained from 189 participants (133 patients for treatment naive lung cancer, 26 healthy volunteers for urine, and 30 healthy volunteers for serum). GM2AP level was detected by Western blotting and quantified using enzyme-linked immunosorbent assay (ELISA). The GM2AP expression in tumors and nontumor parts of lung tissues from 143 nonsmall cell lung cancers was detected by immunohistochemical stains. Results: There was an 8.11 ± 1.36 folds increase in urine and a 5.41 ± 0.73 folds increase in serum level of GM2AP in lung cancer patients compared with healthy volunteers (p < 0.0001), achieving a 0.89 AUC value in urine and 0.90 AUC value in serum for the receiver-operating characteristic curves. Both serum and urine levels of GM2AP correlated significantly with pathology stages (urine, p = 0.009; serum, p < 0.0001). Using immunohistochemical, positive expression of GM2AP was found at 83.9% of nonsmall cell lung cancers patients and none in normal tissue. The GM2AP expression was significantly correlated with pathology stage (p = 0.0001). Patients with higher GM2AP expression had shorter overall survival (p = 0.045) and disease-free survival (p = 0.049) than lower GM2AP expression. Moreover, the multivariate analysis suggested GM2AP as an independent predictors of disease-free survival and overall survival. Conclusions: Our study demonstrates that GM2AP might serve as potential diagnostic and prognostic biomarkers in patients with lung cancer.

[1]  Peterson Pa.  Characteristics of a vitamin A-transporting protein complex occurring in human serum. , 1971 .

[2]  K. Sandhoff,et al.  Biosynthesis, Processing, and Intracellular Transport of GM2 Activator Protein in Human Epidermal Keratinocytes , 1997, The Journal of Biological Chemistry.

[3]  S. Hakomori.  Glycosynapses: microdomains controlling carbohydrate-dependent cell adhesion and signaling. , 2004, Anais da Academia Brasileira de Ciencias.

[4]  Wei Zhang,et al.  Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. , 2012, Cancer letters.

[5]  B. Chewaskulyong,et al.  Human Urinary GM2-activator Protein as a Potential Biomarker for Lung Cancer , 2013 .

[6]  P. A. Peterson.  Characteristics of a vitamin A-transporting protein complex occurring in human serum. , 1971, The Journal of biological chemistry.

[7]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[8]  F. Sharom,et al.  Gangliosides interact with interleukin-4 and inhibit interleukin-4-stimulated helper T-cell proliferation. , 1995, Immunology.

[9]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[10]  J. Check.  CA-125 as a biomarker for malignant transformation of endometriosis. , 2009, Fertility and sterility.

[11]  N. Merchant,et al.  Serum HSP70: A Novel Biomarker for Early Detection of Pancreatic Cancer , 2012, Pancreas.

[12]  D. Mahuran,et al.  Two mechanisms for the recapture of extracellular GM2 activator protein: evidence for a major secretory form of the protein. , 1997, Biochemistry.

[13]  W. Machleidt,et al.  The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein. , 1990, European journal of biochemistry.

[14]  S. Ladisch,et al.  DETECTION OF A TUMOUR-ASSOCIATED GANGLIOSIDE IN PLASMA OF PATIENTS WITH NEUROBLASTOMA , 1985, The Lancet.

[15]  G. Shurin,et al.  Gangliosides as immunomodulators. , 2007, Advances in experimental medicine and biology.

[16]  C. Stock,et al.  Gangliosides in blood serum of normal rats and Morris hepatoma 5123tc-bearing rats. , 1975, Biochemical and biophysical research communications.

[17]  Renee Drabier,et al.  Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood , 2013, BMC Medical Genomics.

[18]  S. Hakomori.  Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. , 1996, Cancer research.

[19]  H. Yeger,et al.  GM2 activator protein inhibits platelet activating factor signaling in rats. , 2009, Biochemical and biophysical research communications.

[20]  Ruixiang Li,et al.  Shedding of human neuroblastoma gangliosides. , 1991, Biochimica et biophysica acta.

[21]  B. Haraldsson,et al.  Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. , 2004, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[22]  U. Schepers,et al.  Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant. , 1996, American journal of human genetics.

[23]  Dan Mercola,et al.  Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer , 2012, PloS one.

[24]  J. Mulshine.  Current issues in lung cancer screening. , 2005, Oncology.

[25]  M. J. Freeman,et al.  Glycolipid-bound sialic acid in serum: increased levels in mice and humans bearing mammary carcinomas. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[26]  K. Sandhoff,et al.  Topology of glycosphingolipid degradation. , 1996, Trends in cell biology.

[27]  Shui-Tein Chen,et al.  Different techniques for urinary protein analysis of normal and lung cancer patients , 2005, Proteomics.

[28]  H. Offner,et al.  Gangliosides induce selective modulation of CD4 from helper T lymphocytes. , 1987, Journal of immunology.

[29]  D. Sok,et al.  Novel fluoroimmunoassay for ovarian cancer biomarker CA-125 , 2009, Analytical and bioanalytical chemistry.

[30]  P. Black.  Shedding from normal and cancer-cell surfaces. , 1980, The New England journal of medicine.

[31]  K. Sandhoff,et al.  Activator proteins and topology of lysosomal sphingolipid catabolism. , 1992, Biochimica et biophysica acta.

[32]  R. Yu,et al.  Role of tumor-associated gangliosides in cancer progression. , 2003, Biochimie.

[33]  S. Ladisch,et al.  Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. , 1992, Cellular immunology.

[34]  L. Valentino,et al.  Localization of shed human tumor gangliosides: association with serum lipoproteins. , 1992, Cancer research.

[35]  Steven E Schild,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[36]  S. Tsim,et al.  Staging of non-small cell lung cancer (NSCLC): a review. , 2010, Respiratory medicine.

[37]  L. Ulsh,et al.  Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides. , 1983, Cancer research.

[38]  K. Fujimori,et al.  Adipokine ganglioside GM2 activator protein stimulates insulin secretion , 2011, FEBS letters.

[39]  Yi Zhu,et al.  Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer , 2011, Chinese journal of cancer.

[40]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[41]  Crawford Js.  Letter: Recycling disposables. , 1974 .